<!DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Strict//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-strict.dtd"><html xml:lang="en" lang="en" xmlns="http://www.w3.org/1999/xhtml"><head><meta http-equiv="Content-Type" content="text/html; charset=utf-8" /><meta name="ROBOTS" content="NOARCHIVE" /><meta name="googlebot" content="nosnippet" /><meta name="Document-Type" content="sub-sub-section" /><meta name="keywords" content="Hormone antagonists: malignant disease; Malignant disease: hormone antagonists; Breast: cancer; Aromatase inhibitors; Anastrozole; Letrozole; Exemestane; Tamoxifen: breast cancer; Hormone antagonists: malignant disease; Malignant disease: hormone antagonists; Goserelin: malignant disease; Progestogens: malignant disease: breast cancer; Bisphosphonates: breast cancer" /><meta name="IX" content="Hormone antagonists: malignant disease; Malignant disease: hormone antagonists; Aromatase inhibitors; Anastrozole; Letrozole; Exemestane; Tamoxifen: breast cancer; Hormone antagonists: malignant disease; Malignant disease: hormone antagonists; Goserelin: malignant disease; Progestogens: malignant disease: breast cancer; Bisphosphonates: breast cancer" /><meta name="IXM" content="Breast: cancer" /><title>8.3.4.1 Breast cancer: British National Formulary</title><link type="text/css" rel="stylesheet" href="../../theme/theme.css" /><link type="text/css" rel="stylesheet" href="../../theme/print.css" media="print" /><link type="text/css" rel="stylesheet" href="265/style.css" /><link type="image/x-icon" rel="shortcut icon" href="favicon.ico" /><link rel="stylesheet" type="text/css" href="style/screen.css" media="screen" /><link rel="stylesheet" type="text/css" href="style/print.css" media="print" /><link rel="contents" type="text/html" href="index.htm" /><link rel="help" type="text/html" href="http://www.medicinescomplete.com/mc/help_page.htm" /><link rel="start" type="text/html" href="index.htm" title="British National Formulary" /><link rel="copyright" type="text/html" href="35091.htm" title="Copyright information" /><link rel="bookmark" title="Skip Navigation" href="4821.htm#pB" /><script type="text/javascript" src="https://ajax.googleapis.com/ajax/libs/jquery/1.7.0/jquery.min.js"></script><script type="text/javascript" src="../../scripts/jquery/jquery.tooltip.min.js"></script><script type="text/javascript" src="../../scripts/jquery/jquery.cookie.js"></script><script type="text/javascript" src="../../scripts/jquery/jquery.autosuggest.js"></script><script type="text/javascript" src="../../scripts/scripts.js"></script><style type="text/css">
  .contentsbox { position: fixed; z-index:1001;}
  .contentsbox_wrap {overflow:hidden;width:20px;height:130px; position:absolute;left:0;top:0;}
</style><!--[if lte IE 7]>
          <style type="text/css">
          .contentsbox {
          position: absolute;
          left: expression( ( 15 + ( ignoreMe2 = document.documentElement.scrollLeft ? document.documentElement.scrollLeft : document.body.scrollLeft ) ) + 'px' );
          top: expression( ( 250 + ( ignoreMe = document.documentElement.scrollTop ? document.documentElement.scrollTop : document.body.scrollTop) ) + 'px' );
          }
          .threecol_col3 {
          font-family: arial
          }
          .threecol_col3 a {
          font-family: verdana,helvetica,sans-serif
          }
          .threecol_col1 {
          font-family: arial
          }
          .threecol_col1 a {
          font-family: verdana,helvetica,sans-serif
          }
          div#pE {
          font-family: arial
          }
          div#pE a {
          font-family: verdana,helvetica,sans-serif
          }
          div#pK {
          font-family: arial
          }
          div#pK a {
          font-family: verdana,helvetica,sans-serif
          }
          </style>
          <![endif]--></head><body><?highlighter off?><div id="pU"><a id="pD" accesskey="s" rel="bookmark" href="4821.htm#pB" title="Skip Navigation">Skip Navigation</a><ul id="pZ"><li><a href="http://www.medicinescomplete.com/mc/account.htm">You are signed in as a member of <b>BNF.org Free Access</b></a></li><li> | <a href="http://www.medicinescomplete.com/mc/login.htm">Sign in different user</a></li><li> | <a href="http://www.medicinescomplete.com/mc/logout.htm">Sign out</a></li></ul><a href="http://www.medicinescomplete.com/mc/" title="Go to the MedicinesComplete home page"><img src="../../images/mc.png" alt="MedicinesComplete" /></a><ul id="pM"><li><a href="http://www.medicinescomplete.com/mc/" class="selected" accesskey="1" title="Home: access key 1"><strong><span>Home</span></strong></a></li><li><a href="http://www.medicinescomplete.com/mc/marketing/current/"><strong><span>Welcome</span></strong></a></li><li><a href="http://www.medicinescomplete.com/mc/feedback.htm?pub=bnf&amp;uri=4821.htm" accesskey="9" title="Feedback: access key 9"><strong><span>Feedback</span></strong></a></li><li><a href="http://www.medicinescomplete.com/mc/help.htm" accesskey="6" title="Help button: access key 6"><strong><span>Help</span></strong></a></li></ul></div><div id="pA"><div id="pY">British National Formulary</div><div id="pG">Printed from: Joint Formulary Committee.  <i>British National Formulary</i>. [online] London: BMJ Group and Pharmaceutical Press.. &lt; http://www.medicinescomplete.com/ &gt; [Accessed on 26 May 2012 (GMT)].</div><div id="pQ"><form id="searchForm" method="get" action="http://www.medicinescomplete.com/mc/bnf/current/search.htm"><fieldset><legend>Details</legend><label for="q">Search for</label><div id="qd"><div><input accesskey="4" type="text" id="q" name="q" /><input class="button" id="searchButton" type="submit" value="Search" name="searchButton" title="Search full text" /></div></div></fieldset></form><script type="text/javascript">$(document).ready(function(){$("#q").autoSuggest('http://www.medicinescomplete.com/mc/bnf/current/search/suggest.xml', {control: "#searchButton"});});</script></div></div><div id="pH"><div id="pN"><div id="pT"><span class="cA"><a href="http://www.medicinescomplete.com/mc/">Home</a></span> &gt; <a href="index.htm">BNF No. 63 (March 2012)</a> &gt; <a href="2075.htm">8 Malignant disease and immunosuppression</a> &gt; <a href="4795.htm">8.3 Sex hormones and hormone antagonists in malignant disease</a> &gt; <a href="4820.htm">8.3.4 Hormone antagonists</a></div><div id="pP"><div class="threecol_col1">◄ <a accesskey="[" href="4820.htm" title="Previous: 8.3.4 Hormone antagonists">Previous page</a></div><div class="threecol_col2"> </div><div class="threecol_col3"><a accesskey="]" href="36794.htm" title="Next: ANASTROZOLE">Next page</a> ►</div></div></div></div><div id="p1"><div id="pB"><h1 id="_4821">8.3.4.1 Breast cancer</h1><?highlighter on?><div id="pC" class="jN"><div><p>The management of patients with breast
cancer involves surgery, radiotherapy, drug therapy, or a combination
of these.</p><p>For operable breast cancer, treatment before surgery (neoadjuvant
therapy) reduces the size of the tumour and facilitates breast-conserving
surgery; hormone antagonist therapy (e.g. letrozole) is chosen for
steroid hormone-receptor-positive breast cancer and chemotherapy for
steroid hormone-receptor-negative tumours or for younger women.</p><div class="cAZ"><h2>Early breast cancer</h2> <p class="cAX">All women should be considered
for adjuvant therapy following surgical removal of the tumour. Adjuvant
therapy is used to eradicate the micrometastases that cause relapses.
Choice of adjuvant treatment is determined by the risk of recurrence,
steroid hormone-receptor status of the primary tumour, and menopausal
status.</p><p>Adjuvant therapy comprises cytotoxic chemotherapy and hormone-antagonist
therapy. Women with steroid hormone-receptor-positive breast cancer
are considered for hormone-antagonist therapy (preceded by cytotoxic
chemotherapy if necessary) whilst women with steroid hormone-receptor-negative
breast cancer should be considered for cytotoxic chemotherapy.</p><p>Aromatase inhibitors act predominantly by blocking the conversion of androgens to oestrogens
in the peripheral tissues. They do not inhibit ovarian oestrogen synthesis
and should not be used in premenopausal women. <b>Anastrozole</b> and <b>letrozole</b> are non-steroidal aromatase inhibitors; <b>exemestane</b> is a steroidal aromatase
inhibitor. Aromatase inhibitors are usually prescribed as initial
adjuvant therapy in postmenopausal women with oestrogen-receptor-positive
tumours; tamoxifen,
an oestrogen-receptor antagonist, is used if an aromatase inhibitor
is not appropriate. Adjuvant hormone antagonist therapy should
generally be continued for 5 years following removal of the tumour.
In postmenopausal women considered for extended adjuvant therapy,
5 years of tamoxifen is followed by letrozole for a further 2–3 years.</p><p>Trastuzumab (<a title="BNF:monograph: TRASTUZUMAB" href="88513.htm#_88513">section 8.1.5</a>) is licensed for use in early
breast cancer which overexpresses human epidermal growth factor-2
(HER2) in women who have received surgery, chemotherapy and radiotherapy
(as appropriate).</p><p>Premenopausal women with oestrogen-receptor-positive breast
cancer who decline chemotherapy may benefit from treatment with goserelin (<a title="BNF:monograph: GOSERELIN" href="4832.htm#_4832">section 8.3.4.2</a>) or ovarian ablation.</p></div><div class="cAZ"><h2>Advanced breast cancer</h2> <p class="cAX">Treatment of advanced breast
cancer depends on the patient’s drug history and an assessment of
disease severity. Aromatase inhibitors, such as anastrozole or letrozole,
are the preferred treatment in postmenopausal women with oestrogen-receptor-positive
advanced breast cancer, a long disease-free interval following treatment
for early breast cancer, and disease limited to bone or soft tissues;
tamoxifen can be used if aromatase inhibitors are not suitable. Progestogens,
such as medroxyprogesterone acetate (<a title="BNF:sub-section: Progestogens" href="4805.htm#_4805">section 8.3.2</a>), may be used after aromatase
inhibitors and tamoxifen in postmenopausal women.</p><p>Tamoxifen should be considered for pre- and perimenopausal women
with oestrogen-receptor-positive breast cancer not previously treated
with tamoxifen. Ovarian suppression is used in pre- and perimenopausal
women who have had disease progression despite treatment with tamoxifen.
The gonadorelin analogue goserelin (<a title="BNF:monograph: GOSERELIN" href="4832.htm#_4832">section 8.3.4.2</a>) is licensed for advanced breast cancer in
pre- and perimenopausal women suitable for hormone manipulation.</p><p>Cytotoxic chemotherapy is indicated for advanced steroid hormone-receptor-negative
tumours and for aggressive disease, particularly when metastases involve
visceral sites (e.g. the liver) or if the disease-free interval following
treatment for early breast cancer is short.</p></div><div id="_4821.2"><div class="cAZ"><h2>Cytotoxic drugs used in breast cancer</h2> <p class="cAX">An anthracycline
combined with fluorouracil (<a title="monograph: FLUOROURACIL" href="4731.htm#_4731">section 8.1.3</a>) and cyclophosphamide (<a title="monograph: CYCLOPHOSPHAMIDE" href="4684.htm#_4684">section 8.1.1</a>), and sometimes also with methotrexate
(<a title="monograph: METHOTREXATE" href="4737.htm#_4737">section 8.1.3</a>) is effective. Cyclophosphamide, methotrexate,
and fluorouracil can be useful if an anthracycline is inappropriate
(e.g. in cardiac disease).</p></div></div><div class="cAZ"><h2>Metastatic disease</h2> <p class="cAX">The choice of chemotherapy
regimen will be influenced by whether the patient has previously received
adjuvant treatment and the presence of any co-morbidity.</p><p>For women who have not previously received chemotherapy, an
anthracycline (such as doxorubicin or epirubicin) alone or in combination
with another cytotoxic drug is the standard initial therapy for metastatic
breast disease.</p><p>Patients with anthracycline-refractory or resistant disease
should be considered for treatment with a taxane (<a title="sub-section: Other antineoplastic drugs" href="4758.htm#_4758">section 8.1.5</a>) either alone or in combination
with trastuzumab if they have tumours that overexpress HER2. Other
cytotoxic drugs with activity against breast cancer include capecitabine
(<a title="sub-section: Antimetabolites" href="4725.htm#_4725">section 8.1.3</a>),  mitoxantrone, mitomycin (both <a title="sub-section: Cytotoxic antibiotics" href="4704.htm#_4704">section 8.1.2</a>), and vinorelbine (<a title="monograph: VINORELBINE" href="65135.htm#_65135">section 8.1.4</a>). Trastuzumab alone (<a title="monograph: TRASTUZUMAB" href="88513.htm#_88513">section 8.1.5</a>) is an option for chemotherapy-resistant cancers
that overexpress HER2. </p></div><div id="_4821.1"><p>The use of <b>bisphosphonates</b> (<a title="sub-section: Bisphosphonates" href="4446.htm#_4446">section 6.6.2</a>) in patients with metastatic
breast cancer may reduce pain and prevent skeletal complications of
bone metastases.</p></div></div></div><?highlighter on?><div id="pS"><p>Sub-sections</p><ul class="jT"><li id="_36794"><a href="36794.htm" title="ANASTROZOLE">ANASTROZOLE</a></li><li id="_86293"><a href="86293.htm" title="EXEMESTANE">EXEMESTANE</a></li><li id="_128316"><a href="128316.htm" title="FULVESTRANT">FULVESTRANT</a></li><li id="_56613"><a href="56613.htm" title="LETROZOLE">LETROZOLE</a></li><li id="_4836"><a href="4836.htm" title="TAMOXIFEN">TAMOXIFEN</a></li><li id="_40598"><a href="40598.htm" title="TOREMIFENE">TOREMIFENE</a></li></ul></div><?highlighter off?><div id="pE">◄ <a accesskey="[" href="4820.htm">Previous: 8.3.4 Hormone antagonists</a> | <a class="top" href="4821.htm#">Top</a> | <a accesskey="]" href="36794.htm">Next: ANASTROZOLE</a> ►</div></div></div><div id="pF"><div id="pL"><div id="footer"><div id="footerinner"><ul><li><a accesskey="0" href="accessibility.htm" title="Accessibility information: access key 0">Accessibility</a> | </li><li><a href="http://www.medicinescomplete.com/mc/marketing/current/contact.htm">Contact Us</a> | </li><li><a href="privacy.htm" title="Privacy Policy">Privacy Policy</a> | </li><li><a accesskey="3" href="http://www.medicinescomplete.com/mc/sitemap.htm" title="Site Map: access key 3">Site Map</a> | </li><li><a accesskey="8" href="terms.htm" title="Terms and Conditions: access key 8">Terms and Conditions</a></li></ul></div></div></div><div id="pX"><p><a href="35091.htm" rel="copyright">Copyright © BMJ Group and the Royal Pharmaceutical Society of Great Britain 2012. All rights reserved.</a></p></div></div><script type="text/javascript">$(document).ready(function(){$.ga('UA-9959526-1');});</script></body></html>